FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | ...

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has signed a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, offering a vast user base and extensive platform resources [1] - The partnership represents a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Company Strengths - Zhiyun Health is a leading platform in chronic disease management, possessing a unique product pipeline and expertise in patient management [1] - The collaboration leverages the strengths of both companies to enhance patient access to medications and health services [1]

Core Viewpoint - The collaboration between Zhiyun Health (09955) and JD Health (06618) aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health, as the largest pharmaceutical e-commerce platform in China, offers a vast user base and extensive platform resources [1] - The partnership represents a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Market Implications - The collaboration is expected to leverage the unique product pipeline and patient management expertise of Zhiyun Health, enhancing the overall service offering [1] - This strategic move aligns with the growing trend of digital health solutions and e-commerce in the pharmaceutical industry [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Lifemin tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, boasting a vast user base and extensive platform resources [1] - The partnership signifies a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Company Strengths - Zhiyun Health is a leading platform in chronic disease management, possessing unique product pipelines and professional capabilities in doctor-patient management [1] - The collaboration leverages the strengths of both companies to enhance patient access to medications and health services [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - This collaboration represents a strong alliance between a leading chronic disease management platform and a prominent e-commerce platform, enhancing the overall service offering to patients [1] - The initiative is positioned to improve patient access to medications and health management services, aligning with the growing trend of digital health solutions in China [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Lifemin tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, boasting a vast user base and extensive platform resources [1] - The partnership signifies a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - The collaboration is expected to leverage Zhiyun Health's unique product pipeline and expertise in chronic disease management [1] - The initiative aims to provide professional full-cycle health management services to patients [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Company Strengths - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, indicating its significant market presence [1] - Zhiyun Health is noted for its leadership in chronic disease management, possessing a unique product pipeline and expertise in patient management [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - This collaboration represents a strong alliance between two leading companies in their respective fields, enhancing the potential for effective promotion of health management solutions [1] - The partnership will facilitate better patient access to medications and health management services, aligning with the growing trend of digital health solutions in China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：9955） 承董事會命 智雲健康科技集團* 有關與京東健康之服務合作協議之 自願性公告 董事長、執行董事兼首席執行官 本公告乃由智雲健康科技集團*（「本公司」，連同其子公司以及併表聯屬實體 統稱為「本集團」）自願作出。本公司董事（「董事」）會（「董事會」）欣然宣佈，本 公司近日與京東健康股份有限公司（「京東健康」，一家於香港聯交所上市的公 司，股份代號：6618.HK）訂立服務合作協議，旨在拓寬莉芙敏片®及其他P2M管 線產品的線上銷售與服務渠道，為患者提供更便捷的購藥體驗與專業的全週 期健康管理服務。 作為中國最大的醫藥電商平台，京東健康具有龐大的用戶基礎及廣泛平台資源， 而作為中國領先的慢病管理平台，本公司擁有獨特的產品管線及醫患管理專 業能力。此次雙方的合作代表強強聯合，將能高效推廣優質且具成本效益的藥 品。 – 1 – 據董事會作出一切合理查詢後所知 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | ...